Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai Bowei Biopharmaceutical
Shanghai, Shanghai, Chinaboweibio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Shanghai Bowei Biopharmaceutical is a clinical-stage Chinese biotechnology company specializing in the development and commercialization of recombinant vaccines. The company's primary focus is on its virus-like particle (VLP) technology platform, which it utilizes to develop high-valence vaccines against Human Papillomavirus (HPV). Its lead candidate is a 9-valent HPV vaccine currently in Phase 3 clinical trials, positioning the company as a significant domestic competitor in the Chinese vaccine market. Beyond HPV, Bowei is expanding its pipeline to include vaccines for other infectious diseases such as shingles and respiratory syncytial virus.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- VaccineRecombinant protein
- Industry
- Biotech
Beyond the preview
Go deeper on Shanghai Bowei Biopharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Bowei Biopharmaceutical.